These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35231678)

  • 1. Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: A prospective study.
    Chen S; Cai D; Lai Y; He J; Wu Q; Huang P; Zhou L; Sun H
    Clin Neurol Neurosurg; 2022 Apr; 215():107189. PubMed ID: 35231678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke.
    Saver JL; Carroll JD; Thaler DE; Smalling RW; MacDonald LA; Marks DS; Tirschwell DL;
    N Engl J Med; 2017 Sep; 377(11):1022-1032. PubMed ID: 28902590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS.
    Diener HC; Chutinet A; Easton JD; Granger CB; Kleine E; Marquardt L; Meyerhoff J; Zini A; Sacco RL
    Stroke; 2021 Mar; 52(3):1065-1068. PubMed ID: 33504190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
    Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
    JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous closure of patent foramen ovale in cryptogenic embolism.
    Meier B; Kalesan B; Mattle HP; Khattab AA; Hildick-Smith D; Dudek D; Andersen G; Ibrahim R; Schuler G; Walton AS; Wahl A; Windecker S; Jüni P;
    N Engl J Med; 2013 Mar; 368(12):1083-91. PubMed ID: 23514285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Follow-Up After Closure of Patent Foramen Ovale in Patients With Cryptogenic Embolism.
    Wintzer-Wehekind J; Alperi A; Houde C; Côté JM; Asmarats L; Côté M; Rodés-Cabau J
    J Am Coll Cardiol; 2019 Jan; 73(3):278-287. PubMed ID: 30678757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke.
    Søndergaard L; Kasner SE; Rhodes JF; Andersen G; Iversen HK; Nielsen-Kudsk JE; Settergren M; Sjöstrand C; Roine RO; Hildick-Smith D; Spence JD; Thomassen L;
    N Engl J Med; 2017 Sep; 377(11):1033-1042. PubMed ID: 28902580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study.
    Paciaroni M; Agnelli G; Bertolini A; Pezzini A; Padovani A; Caso V; Venti M; Alberti A; Palmiero RA; Cerrato P; Silvestrelli G; Lanari A; Previdi P; Corea F; Balducci A; Ferri R; Falcinelli F; Filippucci E; Chiocchi P; Grandi FC; Ferigo L; Musolino R; Bersano A; Ghione I; Sacco S; Carolei A; Baldi A; Ageno W;
    Cerebrovasc Dis; 2011; 31(2):109-16. PubMed ID: 21088390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
    Wiktor DM; Carroll JD
    Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical vs. drug therapy in patients with patent foramen ovale and cryptogenic stroke.
    Liu Y; Wu Y; Xiong L
    Herz; 2021 Jun; 46(3):250-254. PubMed ID: 32394019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcatheter Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke: A Meta-Analysis of Randomized Controlled Trials.
    Darmoch F; Al-Khadra Y; Soud M; Fanari Z; Alraies MC
    Cerebrovasc Dis; 2018; 45(3-4):162-169. PubMed ID: 29597192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke.
    Carroll JD; Saver JL; Thaler DE; Smalling RW; Berry S; MacDonald LA; Marks DS; Tirschwell DL;
    N Engl J Med; 2013 Mar; 368(12):1092-100. PubMed ID: 23514286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.
    Mas JL; Derumeaux G; Guillon B; Massardier E; Hosseini H; Mechtouff L; Arquizan C; Béjot Y; Vuillier F; Detante O; Guidoux C; Canaple S; Vaduva C; Dequatre-Ponchelle N; Sibon I; Garnier P; Ferrier A; Timsit S; Robinet-Borgomano E; Sablot D; Lacour JC; Zuber M; Favrole P; Pinel JF; Apoil M; Reiner P; Lefebvre C; Guérin P; Piot C; Rossi R; Dubois-Randé JL; Eicher JC; Meneveau N; Lusson JR; Bertrand B; Schleich JM; Godart F; Thambo JB; Leborgne L; Michel P; Pierard L; Turc G; Barthelet M; Charles-Nelson A; Weimar C; Moulin T; Juliard JM; Chatellier G;
    N Engl J Med; 2017 Sep; 377(11):1011-1021. PubMed ID: 28902593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis.
    Khan AR; Bin Abdulhak AA; Sheikh MA; Khan S; Erwin PJ; Tleyjeh I; Khuder S; Eltahawy EA
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1316-23. PubMed ID: 24139929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack.
    Li J; Liu J; Liu M; Zhang S; Hao Z; Zhang J; Zhang C
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009938. PubMed ID: 26346232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin or anticoagulation after cryptogenic stroke with patent foramen ovale: systematic review and meta-analysis of randomized controlled trials.
    Romoli M; Giannandrea D; Eusebi P; Cupini LM; Ricci S; Calabresi P
    Neurol Sci; 2020 Oct; 41(10):2819-2824. PubMed ID: 32306140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patent foramen ovale closure in the management of cryptogenic stroke: a review of current literature and guideline statements.
    Elzanaty AM; Patel N; Sabbagh E; Eltahawy EA
    Curr Med Res Opin; 2021 Mar; 37(3):377-384. PubMed ID: 33460329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of Cryptogenic Stroke With Patent Foramen Ovale at Older Ages and Implications for Trials: A Population-Based Study and Systematic Review.
    Mazzucco S; Li L; Rothwell PM
    JAMA Neurol; 2020 Oct; 77(10):1279-1287. PubMed ID: 32628255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Closure or medical therapy for cryptogenic stroke with patent foramen ovale.
    Furlan AJ; Reisman M; Massaro J; Mauri L; Adams H; Albers GW; Felberg R; Herrmann H; Kar S; Landzberg M; Raizner A; Wechsler L;
    N Engl J Med; 2012 Mar; 366(11):991-9. PubMed ID: 22417252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of patent foramen ovale closure or medical therapy after cryptogenic stroke: A meta-analysis of randomized trials.
    Abdelaziz HK; Saad M; Abuomara HZ; Nairooz R; Pothineni NVK; Madmani ME; Roberts DH; Mahmud E
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):176-186. PubMed ID: 29726616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.